“Gross data mismanagement” led to unreliable results that contradicted 30+ years of medical literature, producing a media frenzy that misled consumers and compromised public health.
BOSTON, March, 25, 2014 /PRNewswire/ — Three professional medical societies and a highly distinguished international group of over 130 scientists and concerned physicians have petitioned the Journal of the American Medical Association to retract the article that precipitated recent concerns regarding cardiovascular risks with testosterone therapy. In a letter addressed to the editor-in-chief of JAMA, Dr. Howard Bauchner, the group cites “gross data mismanagement,” rendering the article “no longer credible.” The article by Rebecca Vigen and colleagues was published in the November 13, 2013 issue of JAMA, entitled “Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels.” The results of this article were widely reported as new evidence that testosterone therapy is associated with cardiovascular risks, resulting in a Food and Drug Administration safety bulletin issued January 31, 2014. The retraction letter was written by the Androgen Study Group.
Hormone Therapeutics April 29th, 2014
Tags: cardiovascular risk, data mismanagement, errors, health risk, journal of american medical association, low t, low testosterone, medical article error, medical literature, mistakes, myocardial infarction, public health, quality of life, retract article, risks associated with testosterone therapy, safety, stroke, testosterone therapy, well-being